IL6 and non-small cell lung carcinoma: High IL‐6 expression (>6.37 pg/mL) in advanced NSCLC cases was associated with poor treatment response and short PFS following anti‐PD‐1 therapy, which could be potentially attributed to IL‐6‐mediated blockage of the PD‐1/PD‐L1 axis.